(RTTNews) - Sanofi (SAN.PA, SNY), a French pharmaceutical and healthcare company, on Thursday announced that the Board of Directors had decided not to renew the director mandate of Chief Executive Officer Paul Hudson, with his last day set for February 17, at the close of busines
(RTTNews) - Sanofi (SAN.PA, SNY), a French pharmaceutical and healthcare company, on Thursday announced that the Board of Directors had decided not to renew the director mandate of Chief Executive Officer Paul Hudson, with his last day set for February 17, at the close of busines
Unibail-Rodamco-Westfield SE press release ( UNBLF ): FY Non-GAAP EPS of €9.58. Revenue of €1.87B (-2.6% Y/Y). Total capex invested in 2025 amounted to €1.0 Bn, including JV debt linked to Westfield Wheaton and St James Quarter’s acquisitions. Tenant sales up +3.9% supported by +1.9% increase in footfall vs. 2024. IFRS Net Debt to EBITDA including hybrid improving to 9.1x, down from 9.5x in 2024. ...
Unibail-Rodamco-Westfield SE press release ( UNBLF ): FY Non-GAAP EPS of €9.58. Revenue of €1.87B (-2.6% Y/Y). Total capex invested in 2025 amounted to €1.0 Bn, including JV debt linked to Westfield Wheaton and St James Quarter’s acquisitions. Tenant sales up +3.9% supported by +1.9% increase in footfall vs. 2024. IFRS Net Debt to EBITDA including hybrid improving to 9.1x, down from 9.5x in 2024. Recurring net result of +€1,452 Mn and IFRS net result7 of +€1,268 Mn. Shopping Centre vacancy at 4.6%, down -20 bps vs. 2024. 2026 AREPS forecasted to be in the range of €9.15 to €9.30 with targeted 2026 distribution of €5.50/share. 2026 Guidance: Based on 2025 achievements and timing of disposals, the Group expects its 2026 AREPS to be in a range of €9.15 to €9.30, supported by: • Strong retail operating performance both in Europe (despite lower indexation) and the US; • The positive impact of 2025 and 2026 deliveries; • C&E growth in even years; • Continued focus on cost discipline; and • Lower hybrid financing costs. It also reflects: • €1.6 Bn of disposals completed in 2025 and €0.5 Bn of disposals secured for 2026 (out of which €0.1 Bn already completed); • A negative FX impact with the strengthening of the Euro against the USD and the GBP; and • A slight increase in cost of debt. For fiscal year 2026, the Group targets a distribution of €5.50 per share, representing a c. 60% payout and a c. 22% increase from the €4.50 paid for fiscal year 2025. Asin previous years, guidance assumes no major deterioration of the macro-economic and geopolitical environment. Medium-term outlook Beyond 2026, the Group expects its recurring result to be consistent with the ‘A Platform for Growth’ AREPS targets, reflecting: ▪ Like-for-like NRI performance, including Westfield Rise growth; ▪ Increase in franchising revenues; ▪ Development projects ramp-up and capital recycling; ▪ C&E growth and seasonality; ▪ Partly offset by an increase in financial expenses and FX impact. URW also confirm...
(RTTNews) - French retailer Carrefour Group (CRERF.PK, CRRFY.PK) announced Thursday that it has entered into exclusive negotiations with Paval Holding for the sale of Carrefour Romania, based on an enterprise value of 823 million euros.
(RTTNews) - French retailer Carrefour Group (CRERF.PK, CRRFY.PK) announced Thursday that it has entered into exclusive negotiations with Paval Holding for the sale of Carrefour Romania, based on an enterprise value of 823 million euros.
tadamichi/iStock via Getty Images The closing months of 2025 marked a clear shift in investor behavior. Capital rotated decisively toward income and perceived safety, with substantial inflows into bond and money-market funds and continued outflows from U.S. equity funds, particularly small and mid-caps. That rotation coincided with signs that the Federal Reserve’s tightening cycle was ending, rein...
tadamichi/iStock via Getty Images The closing months of 2025 marked a clear shift in investor behavior. Capital rotated decisively toward income and perceived safety, with substantial inflows into bond and money-market funds and continued outflows from U.S. equity funds, particularly small and mid-caps. That rotation coincided with signs that the Federal Reserve’s tightening cycle was ending, reinforcing a more cautious but opportunistic investment backdrop as markets look toward 2026.¹ This environment has renewed attention on income-oriented assets that can balance stability with selective growth. Bonds, smaller-capitalization equities, and energy infrastructure each offer distinct advantages, but also carry different risks depending on how policy and growth ultimately evolve. Policy, Growth, and Cash Flow Dynamics Fixed income sits at the center of the current allocation debate. After a prolonged bond bear market, higher yields have drawn investors back, particularly toward short- and intermediate-term exposures. Fund-flow data from late 2025 shows some of the strongest bond inflows in years as investors sought income without taking excessive equity risk.² Looking ahead, the appeal of bonds hinges less on aggressive rate cuts and more on policy stability. Even modest easing or a prolonged pause could support bond prices while allowing investors to collect attractive income. At the same time, longer-duration exposure remains sensitive to renewed inflation pressure or stronger-than-expected growth. For income-focused portfolios, this argues for emphasizing quality and maturity discipline rather than reaching for duration. Equities play a more selective role in an income framework. Small-cap stocks have staged a recovery as earnings expectations stabilized into late 2025. Analysts increasingly point to faster projected earnings growth among smaller companies relative to large-cap peers, helped by easing financing conditions and improved operating leverage.³ Still, s...
In December, I said that Chevron (NYSE: CVX) stood out as a top high-yield dividend stock to buy before 2026 -- even better than what I consider to be the best U.S. energy exploration and production company, ConocoPhillips . Both stocks have done phenomenally well year to date, with Chevron up 18.7% and ConocoPhillips rising 15% compared to just a 1.3% gain in the S&P 500 . With Chevron hovering a...
In December, I said that Chevron (NYSE: CVX) stood out as a top high-yield dividend stock to buy before 2026 -- even better than what I consider to be the best U.S. energy exploration and production company, ConocoPhillips . Both stocks have done phenomenally well year to date, with Chevron up 18.7% and ConocoPhillips rising 15% compared to just a 1.3% gain in the S&P 500 . With Chevron hovering around an all-time high, some investors may be concerned that the integrated oil and gas giant has run up too far, too fast. Here's why it's still a good buy now. Continue reading
Panama7/iStock Editorial via Getty Images Sanofi’s ( SNY ) board has decided not to renew the director mandate of Paul Hudson. Hudson joined Sanofi as CEO in September 2019. Previously, he served as CEO of Novartis Pharmaceuticals from 2016 to 2019. His last day as CEO will be February 17, 2026. The board has appointed Belén Garijo as the next CEO. She will officially take over after the company’s...
Panama7/iStock Editorial via Getty Images Sanofi’s ( SNY ) board has decided not to renew the director mandate of Paul Hudson. Hudson joined Sanofi as CEO in September 2019. Previously, he served as CEO of Novartis Pharmaceuticals from 2016 to 2019. His last day as CEO will be February 17, 2026. The board has appointed Belén Garijo as the next CEO. She will officially take over after the company’s Annual General Meeting on April 29, 2026, and her appointment as a director will be submitted for shareholder approval. During the transition, Olivier Charmeil, executive vice president of general medicines, will serve as interim CEO. Garijo, a medical doctor and Spanish national, began her career working in a hospital for six years before moving into the pharmaceutical industry. She worked in R&D at Abbott and then spent 15 years at Sanofi, where she served as vice president of pharmaceutical operations for Europe and Canada and was a member of the executive committee. She joined Merck KGaA in 2011 and became its CEO in 2021 The board said Garijo will focus on strengthening the execution of Sanofi’s strategy, with an emphasis on improving productivity, governance, and innovation in research & development. Source: Press Release More on Sanofi Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi 2025 Q4 - Results - Earnings Call Presentation Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Sanofi anticipates profitable growth to continue over at least five years Sanofi Non-GAAP EPS of €1.53 beats by €0.06, revenue of €11.3B beats by €170M; issues FY26 outlook